Acute Myeloid Leukemia Market (2026-2036)

The growth of this market is mainly driven by the commercial establishment of the menin inhibitor class following two U.S. approvals within twelve months, the establishment of venetoclax-based regimens as the standard of care for patients unfit for intensive chemotherapy, the expansion of mutation-directed therapy across NPM1, KMT2A, FLT3 and IDH-defined subgroups, the ageing demographic profile of the disease, and the broadening of next-generation sequencing at diagnosis, which converts molecular subtypes into addressable treatment populations.

Furthermore, the movement of menin inhibitors into frontline combination regimens, the development of maintenance therapy after transplantation and after remission induction, measurable residual disease-guided treatment intensification, and the extension of oral hypomethylating and oral targeted regimens into community and outpatient settings are expected to offer growth opportunities for the stakeholders in this market.

The Acute Myeloid Leukemia Market comprises the therapeutics used to treat acute myeloid leukemia across induction, consolidation, maintenance and relapsed or refractory settings. The scope spans targeted therapy, including menin inhibitors directed at the menin-KMT2A protein interaction, FLT3 tyrosine kinase inhibitors, IDH1 and IDH2 inhibitors, and the BCL-2 inhibitor venetoclax; hypomethylating agents in injectable and oral forms; conventional cytotoxic chemotherapy, including cytarabine, anthracyclines and liposomal formulations; antibody-drug conjugates and immunotherapeutics; and supportive agents used alongside antileukaemic therapy. The ecosystem includes active pharmaceutical ingredient manufacturers, sterile injectable and oral solid dose contract development and manufacturing organisations, specialty and hospital pharmacies, molecular diagnostics and next-generation sequencing laboratories, haematopoietic cell transplantation centres, academic cooperative groups, payers and reimbursement authorities, and the haematology and oncology practices that deliver treatment.

The characteristics of the disease shape the structure of this market. The National Cancer Institute's Surveillance, Epidemiology, and End Results programme reports a median age at diagnosis of 70 years and an age distribution in which 26.6% of cases are diagnosed between 65 and 74 years, 24.9% between 75 and 84 years, and 10.5% above 84 years, so 62.0% of all diagnoses occur at 65 years or older. Only 4.0% of cases occur below age 20 and 5.2% between 20 and 34. Because a majority of patients are elderly and frequently carry cardiac, renal or performance-status limitations, they are unsuitable for the intensive cytarabine and anthracycline induction regimens that historically defined treatment, and treatment has consequently shifted toward lower-intensity, orally administered regimens that can be delivered in outpatient settings. Acute myeloid leukemia accounts for approximately 1.1% of all new cancer cases in the United States, with an estimated 22,720 new cases and 11,500 deaths projected for 2026, and a five-year relative survival rate of 33.4% for patients diagnosed between 2016 and 2022 under SEER 21 coverage. This survival rate, which is well below the average across all cancers, supports both the continuing clinical urgency in this disease and the willingness of regulators to approve therapies on the basis of single-arm response data.

Globally, the addressable population is considerably larger than United States figures suggest and is distributed differently. The International Agency for Research on Cancer recorded 495,113 new leukaemia cases and 292,234 leukaemia deaths worldwide in 2022, ranking leukaemia twelfth for incidence and ninth for mortality among all cancers. Asia accounted for 237,493 new cases, or 48.0% of the global total, followed by Europe with 104,142 cases, or 21.0%, Northern America with 71,720 cases, or 14.5%, Latin America and the Caribbean with 42,782 cases, or 8.6%, Africa with 31,899 cases, or 6.4%, and Oceania with 7,077 cases, or 1.4%. Acute myeloid leukemia represents a minority of leukaemia incidence but a disproportionate share of leukaemia mortality, because its natural history is measured in weeks to months without treatment. The difference between where cases occur and where therapeutic spending occurs is the defining characteristic of the geographic distribution of this market. The gradual narrowing of this difference through improved access to molecular diagnostics, expanding reimbursement and locally manufactured generics is the principal source of volume growth outside North America and Europe.

Current spending is concentrated in venetoclax-based therapy. AbbVie reported global Venclexta net revenues of USD 2,792 million for 2025, up 8.1% on a reported basis and 7.9% on an operational basis, with fourth-quarter revenues of USD 710 million, up 8.6% reported and 6.4% operationally, inside a total oncology portfolio of USD 6,655 million for the year. Venetoclax is indicated in both chronic lymphocytic leukaemia and acute myeloid leukemia, so only a portion of that revenue is attributable to acute myeloid leukemia, but the combination of venetoclax with azacitidine or with low-dose cytarabine has become the reference regimen for newly diagnosed patients ineligible for intensive chemotherapy and therefore the base layer of market value. The mutation-directed classes are administered around this base and include FLT3 inhibitors such as midostaurin, gilteritinib and quizartinib; IDH inhibitors including ivosidenib, enasidenib and olutasidenib; the antibody-drug conjugate gemtuzumab ozogamicin; the liposomal daunorubicin and cytarabine formulation used in secondary and therapy-related disease; the hedgehog pathway inhibitor glasdegib; and oral hypomethylating agents used for maintenance and for outpatient administration. Injectable azacitidine and decitabine have been genericised, which lowers the cost of the hypomethylating backbone and makes the targeted agent added on top the principal determinant of regimen value.

Another major development reshaping this market is the introduction of the menin inhibitor class. The U.S. Food and Drug Administration approved ziftomenib, marketed as KOMZIFTI by Kura Oncology and Kyowa Kirin, on 13 November 2025 for adults with relapsed or refractory acute myeloid leukemia carrying a susceptible NPM1 mutation and no satisfactory alternative treatment options. Approval rested on the KO-MEN-001 trial, an open-label, single-arm, multicentre study of 112 adults with a median follow-up of 4.2 months, which reported a combined complete remission and complete remission with partial haematologic recovery rate of 21.4%, comprising a 17.0% complete remission rate and a 4.5% complete remission with partial haematologic recovery rate, with a median duration of response of 5.0 months. Revumenib, marketed as Revuforj by Syndax, preceded it, with approval in relapsed or refractory acute leukaemia carrying a KMT2A translocation followed by expansion into relapsed or refractory NPM1-mutated acute myeloid leukemia. Syndax quantifies the opportunity precisely, citing approximately 4,500 relapsed or refractory NPM1-mutated acute myeloid leukemia patients and approximately 2,000 relapsed or refractory KMT2A-translocated acute leukaemia patients annually, a combined population of roughly 6,500 patients, against a stated United States total addressable market above USD 5 billion once frontline settings are included. Commercial uptake has been rapid relative to the population size, with approximately 1,630 patients treated commercially since launch and second-quarter 2026 net revenue of USD 54.7 million, up 91% year over year.

The significance of these two approvals extends beyond their own revenue, because NPM1 mutations are among the most common molecular lesions in adult acute myeloid leukemia, and a class that was first approved for a small relapsed and refractory population therefore has a clear route into a large share of newly diagnosed patients. Kura Oncology and Kyowa Kirin have dosed the first patient in the pivotal Phase 3 KOMET-017 trial of ziftomenib in frontline acute myeloid leukemia, and revumenib is being evaluated in combination with azacitidine and venetoclax in newly diagnosed NPM1-mutated and KMT2A-rearranged disease. If frontline combination data support approval, the menin inhibitor class would move from treating a few thousand relapsed patients a year to being administered alongside the azacitidine and venetoclax backbone in a majority of molecularly eligible newly diagnosed patients, representing the largest single growth opportunity in this market over the forecast period. The clinical rationale is complementary rather than competitive with venetoclax, since the two agents act through distinct mechanisms and triplet regimens are the subject of active late-stage development.

Three further factors are shaping the outlook for this market. First, molecular diagnostics now determine therapy selection. Menin inhibitors require NPM1 mutation or KMT2A translocation status, FLT3 inhibitors require FLT3-ITD or tyrosine kinase domain status, and IDH inhibitors require IDH1 or IDH2 mutation status, so rapid-turnaround next-generation sequencing or targeted panel testing at diagnosis determines whether a patient enters a targeted-therapy pathway. In health systems where molecular testing is unavailable or slow, patients receive chemotherapy or hypomethylating monotherapy regardless of genotype, which limits targeted-therapy penetration. Second, measurable residual disease assessment is moving from a prognostic research tool toward a treatment-decision instrument, with implications for maintenance duration, transplant timing and the design of consolidation regimens. Third, allogeneic haematopoietic cell transplantation remains the only widely available curative treatment for eligible patients, so therapies are increasingly positioned according to their ability to achieve deep remission as a bridge to transplantation and to maintain remission afterwards. This favours agents with manageable outpatient toxicity profiles over maximally intensive regimens.

The competitive environment combines large pharmaceutical companies defending established franchises with specialist haematology companies commercialising first-in-class mechanisms. AbbVie and Genentech hold the venetoclax franchise; Astellas, Novartis and Daiichi Sankyo hold the FLT3 inhibitor positions; Servier and Rigel hold the IDH inhibitor positions; Bristol Myers Squibb, Otsuka and Taiho hold oral hypomethylating positions; Pfizer and Jazz Pharmaceuticals hold antibody-drug conjugate and liposomal chemotherapy positions; and Syndax, Kura Oncology and Kyowa Kirin hold the menin inhibitor positions, with additional menin programmes in clinical development. Generic sterile injectable manufacturers supply cytarabine, anthracyclines, azacitidine and decitabine, which represent a large share of treatment volume and a small share of value. Growth in market value therefore comes almost entirely from new mechanisms administered alongside a genericised chemotherapy and hypomethylating backbone, and the principal commercial objective over the forecast period is the establishment of menin inhibition in frontline combination therapy.